Listed

Resmed Inc: Form 10-Q for the period ended Mar 31, 2025

Filed with the SEC on Apr 24, 2025 and accepted by EDGAR at Apr 23, 2025, 18:20 ET.

Share

Management's discussion and analysis

As filed, 1,489 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Purchases of equity securities. The following table summarizes our purchases of common stock for the three months ended March 31, 2025:

Period Total Number of Shares Purchased Average Price Paid per Share (USD) Total Number of Shares Purchased as Part of Publicly Announced Programs Maximum Number of Shares that May Yet Be Purchased Under the Program
January 1 - 31, 2025 — $— 43,192,913 11,523,100
February 1 - 28, 2025 314,100 238.78 43,507,013 11,209,000
March 1 - 31, 2025 — — 43,507,013 11,209,000
Total 314,100 $238.78 43,507,013 11,209,000

On February 21, 2014, our board of directors approved our current share repurchase program, authorizing us to acquire up to an aggregate of 20.0 million shares of our common stock. The program allows us to repurchase shares of our common stock from time to time for cash in the open market, or in negotiated or block transactions, as market and business conditions warrant and subject to applicable legal requirements. The share repurchase program may be accelerated, suspended, delayed or discontinued at any time at the discretion of our board of directors. All share repurchases after February 21, 2014 have been executed under this program. Since approval of the share repurchase program in 2014 through March 31, 2025, we have repurchased a total of 8.8 million shares under this repurchase program for an aggregate of $762.7 million.

Controls and procedures

As filed, 1,800 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

We maintain disclosure controls and procedures that are designed to provide reasonable assurance that information required to be disclosed in our reports made pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and in reaching a reasonable level of assurance management necessarily was required to apply its judgment in evaluating the cost benefit relationship of possible controls and procedures.

As required by Rule 13a-15(b) of the Exchange Act, we carried out an evaluation, under the supervision and with the participation of our management, including our chief executive officer and chief financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based on the foregoing, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of March 31, 2025.

There has been no change in our internal control over financial reporting during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Risk factors

As filed, 5,487 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The discussion of our business and operations should be read together with the risk factors contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2024 (the "Annual Report"), which was filed with the SEC and describe various material risks and uncertainties to which we are or may become subject. The information presented below updates and should be read in conjunction with the risk factors disclosed in our Annual Report. As of March 31, 2025, there have been no further material changes to such risk factors, except as follows:

Global macroeconomic conditions, including inflation, supply chain disruptions, and fluctuations in foreign currency exchange rates, could continue to adversely affect our operations and profitability. Global economic conditions, geopolitical instability, and other macroeconomic factors, including inflation, supply chain disruptions, such as recent shipping disruptions in the Red Sea, interest rate and foreign currency rate fluctuations, and volatility in the capital markets could negatively impact our business, financial condition, and results of operations. The growth of our business and demand for our products are affected by changes in the health of the overall global economy. Deterioration in the global economic environment may cause decreased demand for our products which could result in lower product sales, lower prices for our products, or reduced reimbursement rates by third-party payors, while increasing the cost of operating our business.

Macroeconomic conditions may impact our global supply chain, primarily through constraints on raw materials and electronic components. These constraints on raw materials and electronic components may also impact companies outside of our direct industry, which could result in a competitive supply environment causing higher costs, requiring us to commit to minimum purchase obligations as well as make upfront payments to our suppliers. These disruptions may impact our ability to produce and supply products in quantities necessary to satisfy customer demand, which could negatively impact our results of operations. Highly competitive and constrained supply chain conditions may increase our cost of sales, which may adversely impact our profitability.

We sell our products in many countries, and we also source many components and materials for our products from and manufacture our products in various countries. The U.S. government recently announced tariffs on product imports from certain countries, including higher tariff levels on those imported from Canada, Mexico, and China. These actions have resulted, and are expected to further result, in retaliatory measures on U.S. goods by those countries and others. If maintained, these recently announced tariffs, and the potential escalation of trade disputes could pose a risk to our business that could affect our revenue and cost of sourcing materials. The extent and duration of the tariffs and the resulting impact on general economic conditions and on our business are uncertain and are expected to be impacted by various factors, such as negotiations between the U.S. and affected countries, the responses of other countries or regions, exemptions or exclusions that already exist or may be granted, availability and cost of alternative sources of our products and materials, and our ability to offset the effects of any tariffs that might be imposed. Specific legislative and regulatory proposals may be introduced to change international trade law, regulations or interpretations thereof (possibly with retroactive effect) of various jurisdictions or limit trade relief benefits that, if enacted, could materially increase the cost of our goods to export internationally, increase our effective tax rate, or have a material adverse impact on our financial condition and results of operation. We cannot predict whether our own or industry initiatives to maintain, extend or create tariff relief for our products and manufacturing will be successful. We also cannot predict the effect, if any, of the imposition of new or increased tariffs by one country and retaliatory responses by other countries who are trade partners. It is possible that these changes could adversely affect our business beyond the resilience of our current supply chain and investment in manufacturing flexibility. Further, actions we take to adapt to new tariffs or trade restrictions may increase our costs or

PART II – OTHER INFORMATION Item 1-6

risks or may cause us to modify our operations, which could be time-consuming and expensive; impact pricing of our products, which could impact our sales, profitability, and our reputation; or cause us to forgo new business opportunities.

Global economic conditions may impact foreign currency exchange rates relative to the U.S. dollar. Although the majority of our net sales and cash generation have been made in the U.S., as our business in countries outside of the U.S. continues to increase, our exposure to foreign currency exchange risk related to our foreign sales and operations will increase. Fluctuations in the rate of exchange between the U.S. dollar and foreign currencies, primarily the Australian Dollar, Singapore Dollar, Euro, Chinese Yuan, and Canadian Dollar, have had and could in the future have an adverse effect on our financial results, including our net sales, margins, gains and losses, as well as on the values of our assets and liabilities.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2025-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2025-01-01 to 2025-03-31$1.29bnus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue9 months2024-07-01 to 2025-03-31$3.80bnus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue3 months2025-01-01 to 2025-03-31$525.3mus-gaap:CostOfGoodsAndServicesSold
Cost of revenue9 months2024-07-01 to 2025-03-31$1.56bnus-gaap:CostOfGoodsAndServicesSold
Gross profit3 months2025-01-01 to 2025-03-31$766.4mus-gaap:GrossProfit
Gross profit9 months2024-07-01 to 2025-03-31$2.23bnus-gaap:GrossProfit
Research and development3 months2025-01-01 to 2025-03-31$83.9mus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2024-07-01 to 2025-03-31$244.8mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative3 months2025-01-01 to 2025-03-31$245.3mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative9 months2024-07-01 to 2025-03-31$725.9mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2025-01-01 to 2025-03-31$426.3mus-gaap:OperatingIncomeLoss
Operating income9 months2024-07-01 to 2025-03-31$1.23bnus-gaap:OperatingIncomeLoss
Income tax3 months2025-01-01 to 2025-03-31$52.7mus-gaap:IncomeTaxExpenseBenefit
Income tax9 months2024-07-01 to 2025-03-31$198.5mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2025-01-01 to 2025-03-31$365.0mus-gaap:NetIncomeLoss
Net income9 months2024-07-01 to 2025-03-31$1.02bnus-gaap:NetIncomeLoss
Diluted EPS3 months2025-01-01 to 2025-03-31$2.48us-gaap:EarningsPerShareDiluted
Diluted EPS9 months2024-07-01 to 2025-03-31$6.93us-gaap:EarningsPerShareDiluted
Basic EPS3 months2025-01-01 to 2025-03-31$2.49us-gaap:EarningsPerShareBasic
Basic EPS9 months2024-07-01 to 2025-03-31$6.96us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2025-01-01 to 2025-03-31147,220,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)9 months2024-07-01 to 2025-03-31147,432,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow9 months2024-07-01 to 2025-03-31$1.21bnus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2024-07-01 to 2025-03-31$59.3mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Dividends paid9 months2024-07-01 to 2025-03-31$233.3mus-gaap:PaymentsOfDividends
Share repurchases9 months2024-07-01 to 2025-03-31$200.0mus-gaap:PaymentsForRepurchaseOfCommonStock
Cash and equivalentsAt period end2025-03-31$932.7mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2025-03-31$3.21bnus-gaap:AssetsCurrent
Total assetsAt period end2025-03-31$7.57bnus-gaap:Assets
Current liabilitiesAt period end2025-03-31$940.5mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2025-03-31$2.02bnus-gaap:Liabilities
Long-term debtAt period end2025-03-31$663.1mus-gaap:LongTermDebt
Short-term borrowingsAt period end2025-03-31$9.9mus-gaap:ShortTermBorrowings
Shareholders' equityAt period end2025-03-31$5.55bnus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0000943819-25-000008. Last ingested by Listed: Nov 14, 2026, 17:21 ET. Listed shows no prices and gives no investment advice.